Physician profile
Jay Chavda
NPI 1386635415
$7,847.37
in general payments reported to CMS, 2019-2025
26 companies · $803 in 2025
The $803 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $306 · 2021: $722 · 2022: $844 · 2023: $2,774 · 2024: $1,821 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,880 · Food and Beverage: $2,496 · Gift: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,880.42 |
| Food and Beverage | $2,495.55 |
| Gift | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,424.66 | 2023 | Fusion, Stealthstation S8 Platform, Nuvent |
| Optinose US, INC. | $1,308.51 | 2019-2025 | |
| Acclarent, INC | $1,155.82 | 2019-2024 | Acclarent Aera, Trudi Nav Cable |
| Integra Lifesciences Corporation | $1,063.79 | 2024 | Inspira Air, Acclarent Aera |
| Glaxosmithkline, LLC. | $581.48 | 2021-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $393.00 | 2022-2025 | Takhzyro, Cuvitru |
| Aerin Medical INC. | $357.83 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $336.06 | 2019-2024 | Dupixent |
| Genzyme Corporation | $200.64 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $196.17 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $128.11 | 2024 | |
| Genentech USA, INC. | $101.64 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $97.72 | 2019 | |
| Grifols USA, LLC | $93.86 | 2025 | Xembify |
| Kowa Pharmaceuticals America, INC. | $67.08 | 2022-2023 | Livalo, Seglentis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $48.81 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals Lp | $39.27 | 2025 | Tezspire |
| Boston Scientific Corporation | $36.46 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $29.01 | 2025 | |
| Sanofi-Aventis U.S. LLC | $27.34 | 2020 | |
| Paratek Pharmaceuticals, INC. | $26.46 | 2025 | Xhance |
| Jubilant Hollisterstier LLC | $24.70 | 2025 | |
| Alk-Abello, INC | $22.21 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $21.00 | 2025 | |
| Merck Sharp & Dohme LLC | $15.74 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Chavda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.